These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12060818)

  • 1. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma.
    Chrischilles E; Delgado DJ; Stolshek BS; Lawless G; Fridman M; Carter WB
    Cancer Control; 2002; 9(3):203-11. PubMed ID: 12060818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
    Morrison VA; Picozzi V; Scott S; Pohlman B; Dickman E; Lee M; Lawless G; Kerr R; Caggiano V; Delgado D; Fridman M; Ford J; Carter WB;
    Clin Lymphoma; 2001 Jun; 2(1):47-56. PubMed ID: 11707870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
    Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
    Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
    Lyman GH; Delgado DJ
    Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe neutropenia and relative dose intensity among patients<65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy.
    Schwartzberg LS; Saleh M; Whittaker S; Abella E
    Support Care Cancer; 2014 Jul; 22(7):1833-41. PubMed ID: 24535242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
    Yokoyama M; Kusano Y; Takahashi A; Inoue N; Ueda K; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
    Support Care Cancer; 2017 Nov; 25(11):3313-3320. PubMed ID: 28551843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.
    Scott SD; Chrischilles EA; Link BK; Delgado DJ; Fridman M; Stolshek BS
    J Manag Care Pharm; 2003; 9(2 Suppl):15-21. PubMed ID: 14613340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Sutheesophon J; Sutcharitchan P; Swasdikul D
    Leuk Lymphoma; 2000 Apr; 37(3-4):351-60. PubMed ID: 10752986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
    Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
    Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma.
    Chrischilles EA; Link BK; Scott SD; Delgado DJ; Fridman M
    Cancer Control; 2003; 10(5):396-403. PubMed ID: 14581895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
    Picozzi VJ; Pohlman BL; Morrison VA; Lawless GD; Lee MW; Kerr RO; Ford JM; Delgado DJ; Fridman M; Carter WB
    Oncology (Williston Park); 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PubMed ID: 11702959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis.
    Kim YR; Kim SJ; Park Y; Oh SY; Yun HJ; Mun YC; Kim JS;
    Korean J Intern Med; 2021 Sep; 36(5):1181-1189. PubMed ID: 34265889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.
    Pettengell R; Bosly A; Szucs TD; Jackisch C; Leonard R; Paridaens R; Constenla M; Schwenkglenks M;
    Br J Haematol; 2009 Mar; 144(5):677-85. PubMed ID: 19055662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
    Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
    Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
    Langeberg WJ; Siozon CC; Page JH; Morrow PK; Chia VM
    Support Care Cancer; 2014 Aug; 22(8):2167-75. PubMed ID: 24652049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis.
    Jacobson JO; Grossbard M; Shulman LN; Neuberg D
    Clin Lymphoma; 2000 Dec; 1(3):211-7; discussion 218. PubMed ID: 11707832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
    Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
    Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.